Loading...
Loading...
SELB| Name | Value |
|---|---|
| Revenues | 5.9M |
| Cost of Revenue | 18.6M |
| Gross Profit | -12.7M |
| Operating Expense | 24.3M |
| Operating I/L | -18.4M |
| Other Income/Expense | -3.3M |
| Interest Income | 0.5M |
| Pretax | -21.7M |
| Income Tax Expense | 4.1M |
| Net Income/Loss | -25.8M |
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's revenue is generated through the development of therapeutic gene therapy programs, biologic therapies, and gene therapies aimed at addressing a range of diseases including chronic refractory gout, IgA-mediated diseases, ornithine transcarbamylase deficiency, and autoimmune diseases. Selecta Biosciences, Inc. also focuses on developing tolerogenic therapies for autoimmune diseases. The company has license and collaboration agreements with several pharmaceutical and biotech companies to support its research and development efforts.
